A business co-founded by Fulton Schools alumnus David Richardson has won one of the Global Health and Pharma Technology Awards for its achievements over the past year. Richardson, who earned a degree in mechanical engineering, is also the CEO of the company, bioSyntagma, which was honored as the “Best Oncology-Focused Precision Medicine Company 2018” by the publication that recognizes global companies for improving public health, enhancing patient care and lowering healthcare costs. bioSyntagma, whose devices help in the discovery of biomarkers, got its start through ASU’s Venture Devils enterprise.